Redivus Health Recognized as Finalist in Fierce Innovation Awards: Healthcare
OLATHE, Kan. — Redivus Health announced that the company has been selected as a finalist in this year’s Fierce Innovation Awards: Healthcare Edition 2017, an awards program from the publisher of FierceHealthcare. Redivus Health was recognized as one of three finalists in the Clinical Information Management category. Redivus Health was selected as a finalist for its innovative, industry-leading product, which improves patient care by providing physicians, nurses and paramedics with actionable, clinical guidance during a critical care event. The Redivus mobile application, combined with a cloud-based platform, delivers evidence-based protocols to enhance diagnostic and treatment accuracy for cardiac arrest, stroke and sepsis. Hospitals and EMS providers using Redivus can expect to reduce risk, improve quality, reduce costs, and increase compliance. All applications were evaluated based on the following criteria: Competitive Advantage, Financial Impact/Value, Market Need, and Overall Innovation. Applicants with the top three scores in each category were selected as finalists. “Everyone deserves safe and effective medical care,” says Jeff Dunn, founder and CEO. “Redivus Health is putting innovation to work to reduce medical error and save lives. We’re thrilled to be recognized along with other companies working to improve today’s healthcare systems.” Finalists were selected by a distinguished panel of judges from renowne...
Rachel L. Wright, Simone Briony Brownless, David Pratt, Catherine M. Sackley, Alan M. Wing
I read with interest the article by Dalen and Alpert.1 Bothersome to me was the selectiveness of the data reported and the somewhat biased resultant interpretation. Consider: they did not mention the pivotal Cryptogenic Stroke and Underlying AF trial,2 in which the unmonitored control group had atrial fibrillation detected in 3% by 36 months, versus 3.7%, 8.9%, 12.4%, and 30.0% at 1, 6, 12, and 36 months, respectively, in the implanted monitor group. Notably, not only was the detection rate frequent with the implanted monitor but also greater than could have occurred with any external monitoring.
Two-thirds of adults and one-third of 11-year-olds in the UK are currently overweight, greatly increasing the risk of heart attacks, strokes, cancer, dementia and diabetes.
AbstractSeveral brain imaging markers have been studied in the development of post-stroke depression (PSD) and post-stroke apathy (PSA), but inconsistent associations have been reported. This systematic review and meta-analysis aims to provide a comprehensive and up-to-date evaluation of imaging markers associated with PSD and PSA. Databases (Medline, Embase, PsycINFO, CINAHL, and Cochrane Database of Systematic Reviews) were searched from inception to July 21, 2016. Observational studies describing imaging markers of PSD and PSA were included. Pooled odds ratios (OR) and 95% confidence intervals (CI) were calculated to ex...
This article is protected by copyright. All rights reserved
CHOLESTEROL can cause heart disease, heart attack, and stroke, but may be lowered through statins. These drugs may also be used to fight infectious diseases, such as malaria and typhoid, according to new research.
Stopping statin therapy after ischaemic stroke should be discouraged to avoid increased risk of another stroke.
This article is protected by copyright. All rights reserved.
(MedPage Today) -- Concerns about coming increases in cases of early ischemic stroke
Analysis Evaluates the Effect of Repatha in More Than 5,000 Patients With a History of Stroke THOUSAND OAKS, Calif., Aug. 21, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the Repatha® (evolocumab) clinical trial program, including three late-breaking scientific sessions, will be presented at the European Society of Cardiology (ESC) Congress 2017 in Barcelona, Spain, Aug. 26-30, 2017. New data includes additional efficacy and safety analyses from the Repatha cardiovascular outcomes trial (FOURIER) and the Repatha coronary intravascular ultrasound imaging trial (GLAGOV). &...